Prostate Cancer Clinical Trial

PSMA PET Imaging of Recurrent Prostate Cancer

Summary

The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Biopsy proven adenocarcinoma of the prostate
Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)

For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy:

PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients
Note: The most recent PSA value must be within 6 weeks of consent

For patients who have received additional treatment in the recurrent or metastatic setting:

° PSA ≥ 2 ng/ml above the most recent therapy nadir

Age ≥ 18 years
Patient must be able to tolerate PET/CT or PET/MR imaging

Exclusion Criteria:

Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

1171

Study ID:

NCT03204123

Recruitment Status:

Active, not recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Memoral Sloan Kettering Basking Ridge (Consent only)
Basking Ridge New Jersey, 07920, United States
Memoral Sloan Kettering Monmouth (Consent only)
Middletown New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Consent only )
Montvale New Jersey, 07645, United States
Memorial Sloan Kettering Commack (Consent only)
Commack New York, 11725, United States
Memoral Sloan Kettering Westchester (Consent only)
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Memorial Sloan Kettering Nassau (Consent only)
Uniondale New York, 11553, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

1171

Study ID:

NCT03204123

Recruitment Status:

Active, not recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.